DEVELOPMENT OF SYSTEMIC ANTISENSE TREATMENT IN DYSTROPHIC MOUSE MODELS FOR DUCHENNE MUSCULAR DYSTROPHY

被引：0
|
作者：
Aartsma-Rus, Annemieke [1 ]
de Winter, Christa [1 ]
van Putten, Maaike [1 ]
Karnaoek, Tatyana [2 ]
van Deutekom, Judith [2 ]
van Ommen, Gert-Jan [1 ]
机构：
[1] Leiden Univ, Dept Human Genet, Med Ctr, NL-2300 RA Leiden, Netherlands
[2] Prosensa BV, Leiden, Netherlands
来源：
NUCLEIC ACID THERAPEUTICS | 2011年 / 21卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：A2 / A2
页数：1
相关论文
共 50 条
  • [1] Development of systemic antisense treatment in dystrophic mouse models for Duchenne muscular dystrophy
    Aartsma-Rus, A. M.
    Tanganyika-de Winter, C. L.
    van Putten, M.
    Karnaoek, T.
    van Deutekom, J. C. T.
    van Ommen, G. J. B.
    NEUROMUSCULAR DISORDERS, 2011, 21 (9-10) : 703 - 703
  • [2] Systemic Antisense-Mediated Exon Skipping in Mouse Models for Duchenne Muscular Dystrophy
    Aartsma-Rus, Annemieke
    Heemskerk, Hans
    De Winter, Christa
    Van Putten, Maaike
    Janson, Anneke
    Verschuuren, Jan
    Den Dunnen, Johan
    Van Deutekom, Judith
    Van Ommen, Gert-Jan
    MOLECULAR THERAPY, 2009, 17 : S166 - S166
  • [3] Results of a systemic antisense study in Duchenne muscular dystrophy
    Muntoni, F.
    Cirak, S. Sebahattin
    Guglieri, M.
    Arechavala, V.
    Morgan, J. E.
    Feng, L.
    Torelli, S.
    Bhardwaj, N.
    Sewry, C. A.
    Straub, V.
    Shrewsbury, S.
    Bushby, K.
    NEUROMUSCULAR DISORDERS, 2010, 20 : S2 - S2
  • [4] Optimization of antisense-mediated exon skipping in mouse models for Duchenne muscular dystrophy
    Aartsma-Rus, A.
    Heemskerk, H. A.
    de Winter, C. L.
    van Putten, M.
    De Kimpe, S.
    van Deutekom, J. C. T.
    van Ommen, G. J. B.
    NEUROMUSCULAR DISORDERS, 2008, 18 (9-10) : 757 - 757
  • [5] Antisense oligonucleotides for the treatment of cardiomyopathy in Duchenne muscular dystrophy
    Quynh Nguyen
    Yokota, Toshifumi
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2019, 11 (03): : 1202 - 1218
  • [6] Development of Antisense-Mediated Exon Skipping as a Treatment for Duchenne Muscular Dystrophy
    Heemskerk, Hans
    de Winter, Christa L.
    van Ommen, Gert-Jan B.
    van Deutekom, Judith C. T.
    Aartsma-Rus, Annemieke
    OLIGONUCLEOTIDE THERAPEUTICS, 2009, 1175 : 71 - 79
  • [7] Resveratrol Ameliorates Muscular Pathology in the Dystrophic mdx Mouse, a Model for Duchenne Muscular Dystrophy
    Hori, Yusuke S.
    Kuno, Atsushi
    Hosoda, Ryusuke
    Tanno, Masaya
    Miura, Tetsuji
    Shimamoto, Kazuaki
    Horio, Yoshiyuki
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2011, 338 (03): : 784 - 794
  • [8] Optimization of preclinical antisense oligonucleotide development for Duchenne muscular dystrophy
    Kolfschoten, I. G. M.
    Janson, A. A. M.
    van den Eijnde, R. E. Y.
    Bijl, S.
    Zonneveld-Mulder, M. H. C.
    de Visser, P. C.
    van Deutekom, J. C. T.
    NEUROMUSCULAR DISORDERS, 2013, 23 (9-10) : 803 - 804
  • [9] Optimizing the efficacy of antisense oligonucleotides for the treatment of Duchenne muscular dystrophy
    Aghaeipour, A.
    Torres-Masjoan, L.
    Aguti, S.
    Zhou, H.
    Muntoni, F.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [10] Investigating the CNS in mouse models for Duchenne muscular dystrophy
    Bagdatlioglu, E.
    Porcari, P.
    O'Hogain, D.
    Greally, E.
    Blamire, A.
    Straub, V.
    NEUROMUSCULAR DISORDERS, 2016, 26 : S6 - S6
12345